Literature DB >> 17702470

Candidiasis--do we need to fight or to tolerate the Candida fungus?

M Raska1, J Bĕláková, M Krupka, E Weigl.   

Abstract

Candidiases, infections caused by germination forms of the Candida fungus, represent a heterogeneous group of diseases from systemic infection, through mucocutaneous form, to vulvovaginal form. Although caused by one organism, each form is controlled by distinct host immune mechanisms. Phagocytosis by polymorphonuclears and macrophages is generally accepted as the host immune mechanism for Candida elimination. Phagocytes require proinflammatory cytokine stimulation which could be harmful and must be regulated during the course of infection by the activity of CD8+ and CD4+ T cells. In the vaginal tissue the phagocytes are inefficient and inflammation is generally an unwanted reaction because it could damage mucosal tissue and break the tolerance to common vagina antigens including the otherwise saprophyting Candida yeast. Recurrent form of vulvovaginal candidiasis is probably associated with breaking of such tolerance. Beside the phagocytosis, specific antibodies, complement, and mucosal epithelial cell comprise Candida eliminating immune mechanisms. They are regulated by CD4+ and CD8+ T cells which produce cytokines IL-12, IFN-gamma, IL-10, TGF-beta, etc. as the response to signals from dendritic cells specialized to sense actual Candida morphotypes. During the course of Candida infection proinflammatory signals (if initially necessary) are replaced successively by antiinflammatory signals. This balance is absolutely distinct during each candidiasis form and it is crucial to describe and understand the basic principles before designing new therapeutic and/or preventive approaches.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17702470     DOI: 10.1007/BF02931313

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.629


  87 in total

1.  Increased tissue resistance in the nude mouse against Candida albicans without altering strain-dependent differences in susceptibility.

Authors:  A Fulurija; R B Ashman; J M Papadimitriou
Journal:  J Med Vet Mycol       Date:  1997 May-Jun

2.  Growth inhibition of Candida by human oral epithelial cells.

Authors:  C Steele; J Leigh; R Swoboda; P L Fidel
Journal:  J Infect Dis       Date:  2000-10-09       Impact factor: 5.226

Review 3.  Candida, still number one--what do we know and where are we going from there?

Authors:  Esther Segal
Journal:  Mycoses       Date:  2005       Impact factor: 4.377

4.  Cellular and cytokine correlates of mucosal protection in murine model of oral candidiasis.

Authors:  S Elahi; G Pang; R Clancy; R B Ashman
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Acute systemic candidiasis in normal and congenitally thymic-deficient (nude) mice.

Authors:  J E Cutler
Journal:  J Reticuloendothel Soc       Date:  1976-02

Review 6.  Biology of the pathogenic yeast Candida glabrata.

Authors:  A Bialková; J Subík
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

7.  Both CD4+ and CD8+ lymphocytes reduce the severity of tissue lesions in murine systemic cadidiasis, and CD4+ cells also demonstrate strain-specific immunopathological effects.

Authors:  R B Ashman; A Fulurija; J M Papadimitriou
Journal:  Microbiology       Date:  1999-07       Impact factor: 2.777

Review 8.  An outline of the role of anti-Candida antibodies within the context of passive immunization and protection from candidiasis.

Authors:  A Cassone; F De Bernardis; A Torososantucci
Journal:  Curr Mol Med       Date:  2005-06       Impact factor: 2.222

9.  Candida-specific systemic cell-mediated immune reactivities in human immunodeficiency virus-positive persons with mucosal candidiasis.

Authors:  J E Leigh; M Barousse; R K Swoboda; T Myers; S Hager; N A Wolf; J L Cutright; J Thompson; J D Sobel; P L Fidel
Journal:  J Infect Dis       Date:  2000-12-13       Impact factor: 5.226

10.  Involvement of interleukin-18 in the inflammatory response against oropharyngeal candidiasis.

Authors:  François Tardif; Jean-Paul Goulet; Andrew Zakrazewski; Peter Chauvin; Mahmoud Rouabhia
Journal:  Med Sci Monit       Date:  2004-07-23
View more
  6 in total

1.  Molecular adjuvants based on nonpyrogenic lipophilic derivatives of norAbuMDP/GMDP formulated in nanoliposomes: stimulation of innate and adaptive immunity.

Authors:  Pavlína Turánek Knotigová; Daniel Zyka; Josef Mašek; Anna Kovalová; Michal Křupka; Eliška Bartheldyová; Pavel Kulich; Štěpán Koudelka; Róbert Lukáč; Zuzana Kauerová; Antonín Vacek; Milada Stuchlová Horynová; Alois Kozubík; Andrew D Miller; Ladislav Fekete; Irena Kratochvílová; Jan Ježek; Miroslav Ledvina; Milan Raška; Jaroslav Turánek
Journal:  Pharm Res       Date:  2015-01-30       Impact factor: 4.200

2.  Mutants of Candida albicans hypersensitive to calcofluor white display susceptibility to antifungal drugs.

Authors:  Zhu-Mei He; Jing Chen; Hong-Zhou Li; Di-Qing Luo; Wei Yang
Journal:  Folia Microbiol (Praha)       Date:  2010-05-19       Impact factor: 2.099

Review 3.  Yeasts in the gut: from commensals to infectious agents.

Authors:  Jürgen Schulze; Ulrich Sonnenborn
Journal:  Dtsch Arztebl Int       Date:  2009-12-18       Impact factor: 5.594

4.  The changes of antifungal susceptibilities caused by the phenotypic switching of Candida species in 229 patients with vulvovaginal candidiasis.

Authors:  Yuanting Tang; Fan Yu; Lairong Huang; Zhengqiang Hu
Journal:  J Clin Lab Anal       Date:  2018-08-12       Impact factor: 2.352

5.  Screening of potential genes contributing to the macrocycle drug resistance of C. albicans via microarray analysis.

Authors:  Jing Yang; Wei Zhang; Jian Sun; Zhiqin Xi; Zusha Qiao; Jinyu Zhang; Yan Wang; Ying Ji; Wenli Feng
Journal:  Mol Med Rep       Date:  2017-09-20       Impact factor: 2.952

6.  Role of bacterial lipopolysaccharide in enhancing host immune response to Candida albicans.

Authors:  Helen Rogers; David W Williams; Gui-Jie Feng; Michael A O Lewis; Xiao-Qing Wei
Journal:  Clin Dev Immunol       Date:  2013-01-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.